Diaxonhit Share Price Euronext Paris
Stocks
FR0004054427
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 214M 244M 200M 183M 344M 23.39B 349M 2.37B 927M 11.55B 916M 896M 39.93B | P/E 2026 * |
18.8x | P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 182M 208M 170M 156M 293M 19.9B 297M 2.02B 788M 9.83B 779M 762M 33.97B | EV / Sales 2026 * |
1.04x | EV / Sales 2027 * | - |
| Free-Float |
98.24% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -1.83% |
| Manager | Title | Age | Since |
|---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | 58 | 12/06/2023 |
Olivier Bosc
DFI | Director of Finance/CFO | - | 09/10/2023 |
Maarten Penning
CTO | Chief Tech/Sci/R&D Officer | - | 30/06/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 31/12/2018 | |
Michel Picot
BRD | Director/Board Member | 73 | 26/06/2019 |
| Director/Board Member | 69 | 14/06/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.83% | -.--% | - | - | 244M | |
| +0.18% | -0.53% | -0.74% | +11.18% | 47.74B | |
| -0.61% | +4.26% | +396.16% | +647.20% | 39.98B | |
| 0.00% | +4.93% | +11.81% | +55.56% | 36.23B | |
| +2.48% | +4.57% | +7.05% | -5.05% | 35.59B | |
| +0.62% | +3.53% | +5.41% | +42.19% | 27.91B | |
| -2.00% | +11.64% | +31.71% | +136.81% | 16.45B | |
| -0.17% | +0.66% | - | - | 16.71B | |
| +0.18% | -3.93% | +2.29% | +7.38% | 13.21B | |
| +1.82% | +1.56% | -9.75% | -30.15% | 12.93B | |
| Average | +0.05% | +2.77% | +55.49% | +108.14% | 27.42B | |
| Weighted average by Cap. | +0.32% | +2.94% | +74.16% | +136.40% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 176M 200M 164M 150M 282M 19.19B 286M 1.95B 760M 9.47B 751M 735M 32.75B | - |
| Net income | 11.6M 13.2M 10.8M 9.92M 18.62M 1.27B 18.87M 128M 50.13M 625M 49.53M 48.47M 2.16B | - |
| Net Debt | -32M -36.4M -29.79M -27.36M -51.37M -3.49B -52.05M -354M -138M -1.72B -137M -134M -5.96B | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
